KPRX Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Kiora Pharmaceuticals Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerKPRX

Market Cap12.5M

Cash RunwayRunway > 12 months

Next Catalyst2026-11

Public Research Snapshot

Kiora Pharmaceuticals Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for KIO-301 in Late-stage Retinitis Pigmentosa (ABACUS-2) NCT06628947 (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
KIO-301	Late-stage Retinitis Pigmentosa (ABACUS-2) NCT06628947	n/a	Phase 2	Public pipeline row
KIO-104	Macular Edema NCT06825702	Small Molecule	Phase 2	Public pipeline row
ABACUS-2	RP who have profound vision loss	n/a	Phase 2	Public pipeline row
Upcoming Event	retinal disease	n/a	n/a	Public pipeline row
Results from preclinical study KIO-104 released	Phase 2 Clinical Trial of its Photoswitch for Advanced RP	n/a	Phase 2	Public pipeline row
KIO-101	Dry Eye Disease	n/a	Phase 2	Public pipeline row
100 μg KIO-301	Retinitis Pigmentosa	n/a	Phase 2	Public pipeline row
KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)	Persistent Corneal Epithelial Defect	n/a	Phase 2	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Clinical Trial Completion	2026-11	KIO-104	Low
Clinical Trial Completion	2027-08	100 μg KIO-301	Low
Data Readout	Timing not specified	n/a	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05436288	Phase 2	COMPLETED	10	2022-12-22
NCT05282953	Phase 1 \| Phase 2	COMPLETED	32	2023-08-10
NCT05629364	Phase 2	TERMINATED	4	2024-01-09
NCT06825702	Phase 2	RECRUITING	28	2026-11
NCT06628947	Phase 2	RECRUITING	36	2027-08

Scientific Context

catalyst_type | Data Readout
literature_publication | Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.
literature_publication | Immunology of Uveitis - From Bench to Bedside.
literature_publication | Can intraocular pressure serve as a non-invasive surrogate marker for intracranial pressure following traumatic brain injury?
literature_publication | A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - A phase I clinical trial.

Want the full KPRX research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.